2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase
  5. Carbonic Anhydrase Inhibitor

Carbonic Anhydrase Inhibitor

Carbonic Anhydrase Isoform Comparison

Carbonic Anhydrase Inhibitors (113):

Cat. No. Product Name Effect Purity
  • HY-13650
    Indisulam
    		Inhibitor 99.60%
    Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15.
  • HY-B0782
    Acetazolamide
    		Inhibitor 99.89%
    Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities.
  • HY-13513
    U-104
    		Inhibitor 99.91%
    U-104 (SLC-0111) is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki values of 45.1 nM and 4.5 nM, respectively. U-104 shows a significant delay in tumor growth in mice model.
  • HY-B0553
    Methazolamide
    		Inhibitor 99.43%
    Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders.
  • HY-B1480
    Ethoxzolamide
    		Inhibitor 99.43%
    Ethoxzolamide is a carbonic anhydrase inhibitor with Ki of 1 nM.
  • HY-152140
    hCAII-IN-8
    		Inhibitor
    hCAII-IN-8, an amide, is a highly selective carbonic anhydrase (CA) inhibitor with an IC50 value of 0.18 μM against hCA II.
  • HY-148135
    hCAI/II-IN-6
    		Inhibitor ≥98.0%
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy.
  • HY-B0124
    Zonisamide
    		Inhibitor 99.94%
    Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
  • HY-B0122
    Topiramate
    		Inhibitor ≥98.0%
    Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
  • HY-B0109A
    Dorzolamide hydrochloride
    		Inhibitor 99.91%
    Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
  • HY-B0588
    Brinzolamide
    		Inhibitor 99.61%
    Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research.
  • HY-B1424
    Benzthiazide
    		Inhibitor 99.70%
    Benzthiazide is a long-acting diuretic and a hypertension agent. Benzthiazide is an inhibitor of carbonic anhydrase 9 (CA9), with Kis of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells.
  • HY-B0397
    Dichlorphenamide
    		Inhibitor 98.90%
    Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research.
  • HY-108316
    Sultiame
    		Inhibitor 99.76%
    Sultiame is a carbonic anhydrase inhibitor, widely used as an antiepileptic drug.
  • HY-118467
    Benzolamide
    		Inhibitor 98.07%
    Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures.
  • HY-B0483
    Tioxolone
    		Inhibitor 98.83%
    Tioxolone, a metalloenzyme carbonic anhydrase I inhibitor, is an anti-acne preparation.
  • HY-B1471
    Fluorometholone acetate
    		Inhibitor 98.54%
    Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonic anhydrase (CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research.
  • HY-P99023
    Girentuximab
    		Inhibitor 99.39%
    Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).
  • HY-138365
    EMAC10101d
    		Inhibitor 99.89%
    EMAC10101d is a potent and selective toward hCA II inhibitor, with a Ki of 8.1 nM.
  • HY-B2147
    2-Aminobenzenesulfonamide
    		Inhibitor 99.80%
    2-Aminobenzenesulfonamide is a carbonic anhydrase IX inhibitor.